- |||||||||| ivermectin oral / Generic mfg., ivermectin topical / Generic mfg.
Acute Visual Disturbances and Ataxia Secondary to Attempted COVID-19 Prophylaxis with Ivermectin (Anaheim Convention Center, Hall A, Board # 190) - Nov 10, 2022 - Abstract #AAPNCE2022AAP_NCE_2283; We present a case of a 6-year-old female with neurotoxicity following a ten-fold overdose of ivermectin for COVID-19 prophylaxis. With the increasing off-label use of ivermectin for attempted COVID-19 prophylaxis, we use this example to illustrate the symptoms of ivermectin toxicity in children to help identify ingestion events earlier.
- |||||||||| ivermectin oral / Generic mfg.
Journal: The National COVID-19 Clinical Evidence Taskforce: pregnancy and perinatal guidelines. (Pubmed Central) - Nov 9, 2022 Finally, there are recommendations not to use several disease-modifying treatments for the treatment of COVID-19, including hydroxychloroquine and ivermectin. The recommendations are continually updated to reflect new evidence, and the most up-to-date guidance is available online (https://covid19evidence.net.au).
- |||||||||| ivermectin oral / Generic mfg.
Review, Journal: Medications for early treatment of COVID-19 in Australia. (Pubmed Central) - Nov 9, 2022 Several drugs with different modes of action are approved in Australia for early treatment of COVID-19, including nirmatrelvir plus ritonavir, molnupiravir, and monoclonal antibody formulations...Other treatments, including hydroxychloroquine, ivermectin and dietary supplements, have been popularised but are not recommended for early treatment of COVID-19...As it stands, early treatment of COVID-19 needs to be individualised depending on age, pregnancy status, existing medications, and renal and liver disease status. Future treatments in development might have roles in patients with lower risk profiles and in reducing transmission as we learn to live with SARS-CoV-2.
- |||||||||| ivermectin oral / Generic mfg., ivermectin topical / Generic mfg.
Journal: Central effects of Ivermectin in alleviation of Covid-19-induced dysautonomia. (Pubmed Central) - Nov 4, 2022 IVM activates both GABA-ergic neurons and nAChRs to mitigate SARS-CoV-2 infection-induced dysautonomia. Therefore, in this brief report, we try to identify the potential role of IVM in the management of Covid-19-induced dysautonomia.
- |||||||||| ivermectin oral / Generic mfg., albendazole / Generic mfg.
Review, Journal: Ivermectin and albendazole coadministration: opportunities for strongyloidiasis control. (Pubmed Central) - Nov 2, 2022 Finally, the evolution of ivermectin resistance represents a credible risk to control S stercoralis; we argue that genome-wide approaches, together with improved genome resources, are needed to characterise and prevent the emergence of resistance. Overcoming these challenges will help to reduce strongyloidiasis burden and enhance the feasibility of controlling it worldwide.
- |||||||||| Review, Journal: Anthelmintic intoxication in goats and sheep: A systematic review. (Pubmed Central) - Nov 2, 2022
The most prevalent symptoms of anthelmintic intoxication reported were showed involvement of the nervous, locomotor, and renal systems, as well as teratogenic influences. Data from this review underscore the need of the care required in the control of parasitic infections through the safe use of antiparasitic drugs to avoid cases of intoxication.
- |||||||||| ivermectin oral / Generic mfg.
Retrospective data, Journal: Early Outpatient Treatment of COVID-19: A Retrospective Analysis of 392 Cases in Italy. (Pubmed Central) - Oct 28, 2022 The most frequently prescribed drugs included: vitamins and supplements (98.7%), aspirin (66.1%), antibiotics (62%), glucocorticoids (41.8%), hydroxychloroquine (29.6%), enoxaparin (28.6%), colchicine (8.9%), oxygen therapy (6.9%), and ivermectin (2.8%)...The drug use described in this study appears effective and safe. The present evidence should be carefully considered by physicians and political decision makers.
- |||||||||| moxidectin / Generic mfg., ivermectin oral / Generic mfg., albendazole / Generic mfg.
Journal: Current pharmacotherapeutic strategies for Strongyloidiasis and the complications in its treatment. (Pubmed Central) - Oct 28, 2022 Moxidectin might be a valid alternative to ivermectin, with the advantage of being a dose-independent formulation...In pregnant or lactating women, studies have not identified increased risk with ivermectin use. However, with limited available data, a risk-benefit assessment should be considered for each case.
- |||||||||| Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Review, Journal: Molnupiravir in COVID-19: A scoping review. (Pubmed Central) - Oct 27, 2022 On the basis of the limited evidence available as of now, molnupiravir could prove to be a promising oral therapy, worthy of further exploration of its utility for both treatment and prevention of COVID-19 in humans. Elaborate clinical evaluation is further warranted to confirm whether the results are replicable to the clinical scenario among outpatients to reduce the chance of progression to more severe disease.
- |||||||||| moxidectin / Generic mfg., ivermectin oral / Generic mfg.
Review, Journal: Strongyloides stercoralis: A Neglected but Fatal Parasite. (Pubmed Central) - Oct 27, 2022 In contrast, treatment is simple: administration of single dosage ivermectin or moxidectin, a recent anthelmintic drug...Thus, disease manifestation awareness among clinicians is crucial. Furthermore, active surveillance and advanced diagnostic tests are essential for fundamental management.
- |||||||||| ivermectin oral / Generic mfg.
Journal: The effect of Ivermectin on cases of COVID-19. (Pubmed Central) - Oct 26, 2022 Adult patients with active COVID-19 infection who were not prescribed Ivermectin (n = 797,285 Outpatient, n = 481,705 Inpatient, and n = 58,050 Intensive care unit), and those prescribed Ivermectin (n = 804 Outpatient, n = 1774 Inpatient, and n = 107 Intensive care unit) were evaluated. The cohorts were then evaluated for mortality comparing patients prescribed Ivermectin and those not prescribed Ivermectin in the Outpatient (7.7 % vs 2.2 %, P < 0.001), Inpatient not requiring Intensive Care (15.6 % vs 7.2 %, P ≤ 0.001), and Intensive care (20.6 % vs 19.6 %, P = 0.86) treatment settings.
|